Ardelyx, Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017. Ardelyx is a clinical-stage biopharmaceutical company focused on gastrointestinal and cardiorenal therapies. It had no approved products and generated no revenue in the quarter.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 / prior balance-sheet date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $22.4 million | $19.3 million |
| General and administrative expense | $6.0 million | $4.3 million |
| Total operating expenses / operating loss | $28.4 million / $(28.4) million | $23.5 million / $(23.5) million |
| Net loss | $(28.0) million | $(23.5) million |
| Net loss per share, basic and diluted | $(0.59) | $(0.70) |
| Net cash used in operating activities | $(26.8) million | $(16.2) million |
| Cash, cash equivalents and short-term investments | $173.4 million | $200.8 million at Dec. 31, 2016 |
| Total assets / total liabilities | $187.8 million / $20.1 million | $213.1 million / $20.0 million at Dec. 31, 2016 |
As a pre-revenue company, gross margin is not applicable. The filing reports no debt or credit facility; it states that Ardelyx has no committed sources of capital. Contractual obligations totaled $9.1 million, including $7.9 million of operating leases and $1.2 million of purchase commitments.
Changes versus the prior comparable quarter
- Operating expenses increased 21% overall: R&D rose 16%, while G&A rose 41%. Management attributed higher R&D primarily to increased personnel, facilities and internal program costs; lower tenapanor external costs partly offset increased costs for RDX7675 and RDX8940. Higher G&A reflected increased personnel, stock-based compensation and professional fees.
- Net loss increased by $4.5 million, while loss per share improved from $0.70 to $0.59, primarily in the context of a larger weighted-average share count (47.3 million versus 33.5 million).
- Operating cash use increased by $10.5 million. Cash and investments declined $27.4 million from year-end. Investing cash inflow of $23.0 million mainly reflected maturities and sales of investments, not operating income. Q1 2016 financing had included $80.8 million of net public-offering proceeds; Q1 2017 financing was $0.4 million, mainly from stock plans.
Outlook, risks and other notable matters
- Management said existing capital resources were expected to fund projected operating requirements for at least 12 months from March 31, 2017, but cautioned that assumptions may prove incorrect. The company expects substantial additional capital needs and may seek financing or collaborations; availability and terms are uncertain.
- Management expects substantial R&D investment to continue, with G&A also expected to rise to support development and potential commercialization. No revenue or earnings guidance was provided.
- Pipeline status: tenapanor was in Phase 3 development for IBS-C and hyperphosphatemia in dialysis patients; RDX7675 was in Phase 3 development for hyperkalemia; RDX8940 had an IND filed in late 2016 and was advancing toward Phase 1.
- Key risks include clinical-trial failure or delay, regulatory approval and manufacturing uncertainty, dependence on third-party manufacturers and clinical research organizations, future financing needs, competition, and uncertain pricing and reimbursement. Tenapanor-related adverse effects reported in studies included gastrointestinal symptoms and electrolyte changes.
- The filing identifies no material pending litigation, no off-balance-sheet arrangements, and no subsequent events. Management concluded disclosure controls were effective at a reasonable assurance level as of March 31, 2017.
Important facts for investors to verify
- Whether the stated 12-month liquidity runway remains supported by actual spending, trial costs and development timelines.
- Progress, results and timing of the Phase 3 tenapanor and RDX7675 programs, and advancement of RDX8940.
- Expected financing needs and the availability, dilution and terms of potential equity, debt or collaboration funding.
- Clinical safety, manufacturing capacity, regulatory requirements, and the competitive and reimbursement outlook for each target market.